Nanoform Finland (OSTO:NANOFS) EBITDA Margin % : -885.16% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nanoform Finland's EBITDA for the three months ended in Mar. 2024 was kr-60.31 Mil. Nanoform Finland's Revenue for the three months ended in Mar. 2024 was kr6.81 Mil. Therefore, Nanoform Finland's EBITDA margin for the quarter that ended in Mar. 2024 was -885.16%.

Nanoform Finland EBITDA Margin % Historical Data

The historical data trend for Nanoform Finland's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland EBITDA Margin % Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-14,211.87

-2,617.75

-879.35

-557.95

-695.56

Nanoform Finland Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-456.73	-586.25	-466.93	-2,030.69	-885.16

Competitive Comparison of Nanoform Finland's EBITDA Margin %

For the Biotechnology subindustry, Nanoform Finland's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoform Finland's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's EBITDA Margin % falls into.

Nanoform Finland EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nanoform Finland's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-199.648	/	28.703
	=	-695.56 %

Nanoform Finland's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-60.306	/	6.813
	=	-885.16 %

Nanoform Finland (OSTO:NANOFS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nanoform Finland EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoform Finland (OSTO:NANOFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

NANOFH:Finland 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines